No, a urine pregnancy test is NOT required before every Depo-Provera injection if the patient is on time
If the patient returns within the recommended timeframe (up to 15 weeks from the last injection), you can proceed with the injection without obtaining a pregnancy test. The key is ensuring the patient is not late—meaning they are within 2 weeks of their scheduled 13-week reinjection date.
When Pregnancy Testing is NOT Required
According to CDC guidelines, the repeat DMPA injection can be given up to 2 weeks late (15 weeks from the last injection) without requiring additional contraceptive protection 1, 2. This grace period exists because:
- DMPA provides contraceptive coverage that extends beyond the 13-week dosing interval
- Pregnancy rates remain extremely low during this window
- The method's mechanism of action (ovulation suppression) persists through this timeframe
For on-time patients (≤15 weeks since last injection):
When Pregnancy Testing IS Required
If the patient is MORE than 2 weeks late (>15 weeks from last injection):
- You must determine that the patient is not pregnant before administering the drug 4
- Use the "reasonably certain not pregnant" checklist 1
- She needs to abstain from intercourse or use backup contraception for 7 days after the injection 1
- Consider emergency contraception if she had unprotected intercourse in the preceding days 1
The "Reasonably Certain Not Pregnant" Approach
The CDC provides specific criteria to determine pregnancy status without mandatory testing. A patient can be considered not pregnant if she has:
- No symptoms or signs of pregnancy, AND
- Meets one of several timing criteria (e.g., within 7 days after menses started, <7 days post-abortion, exclusively breastfeeding and amenorrheic <6 months postpartum, etc.) 1
Clinical Pearls
Scheduling strategy: Many providers schedule adolescents every 11-12 weeks rather than 13 weeks to allow for missed or delayed visits while staying within the grace period 5. This practical approach reduces the likelihood of needing pregnancy testing and maintains continuous contraceptive coverage.
Documentation matters: The FDA label states that "if the time interval between injections is greater than 13 weeks, the physician should determine that the patient is not pregnant before administering the drug" 4. This doesn't mandate urine testing—clinical assessment using the "reasonably certain" criteria is acceptable 1.
No routine follow-up required: Beyond the injection visits, no routine monitoring is necessary, though patients should be encouraged to contact you with concerns 2.
The evidence consistently supports that routine pregnancy testing before every on-time Depo injection is unnecessary and creates an unwarranted barrier to contraceptive access 1, 2.